<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04972604</url>
  </required_header>
  <id_info>
    <org_study_id>CD-2021-01</org_study_id>
    <nct_id>NCT04972604</nct_id>
  </id_info>
  <brief_title>CureDuchenne Link™: A Resource for Research</brief_title>
  <acronym>CDLink</acronym>
  <official_title>CureDuchenne Link™: A Resource to Support Research Studies in Duchenne and Becker Muscular Dystrophy (DMD/BMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CureDuchenne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CureDuchenne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CureDuchenne link is a data hub comprised of integrated biospecimens, clinical data, and&#xD;
      self- and/or caregiver-reported information from participants. Anyone over 4 weeks old who&#xD;
      has been diagnosed with DMD or BMD or who is a carrier of DMD or BMD can join. Parents or&#xD;
      legal guardians can sign up their child(ren).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Individuals can participate through the CureDuchenne Link™ application (accessible via mobile&#xD;
      device or web interface) and receive communications about research opportunities and&#xD;
      community programs. Participation may be done using virtual methods, at a project site,&#xD;
      and/or at community events nationwide.&#xD;
&#xD;
      All collected information will be stored in a secure, HIPAA-compliant data warehouse for&#xD;
      approved researchers to use for studies relevant to DMD, BMD and other neuromuscular&#xD;
      disorders. Combining health and outcomes data with biospecimens provides an impactful&#xD;
      solution and novel resource for researchers, allowing for effective translational research.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 9, 2021</start_date>
  <completion_date type="Anticipated">July 9, 2031</completion_date>
  <primary_completion_date type="Anticipated">July 9, 2031</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Diagnosis</measure>
    <time_frame>Upon study entry</time_frame>
    <description>There is no intervention in this project. Participants will provide documentation to support their diagnosis of Duchenne muscular dystrophy, Becker muscular dystrophy, or a carrier of these mutations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Genetic Mutation</measure>
    <time_frame>Upon study entry or when genetic testing results are available</time_frame>
    <description>Participants will be asked to provide genetic testing reports confirming their diagnosis, where available, which will be reviewed by a central genetic counselor.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional Status</measure>
    <time_frame>Upon study entry and every 6-12 months thereafter for up to ten (10) years</time_frame>
    <description>Self reported data (questionnaire on ambulation and mobility) will be captured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>North Star Ambulation Assessment (NSAA) Score</measure>
    <time_frame>Upon study entry and every 6-12 months thereafter for up to ten (10) years</time_frame>
    <description>Clinically reported NSAA scores will be captured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 Minute Walk Test (6MWT) Score</measure>
    <time_frame>Upon study entry and every 6-12 months thereafter for up to ten (10) years</time_frame>
    <description>Clinically reported 6MWT scores will be captured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corticosteroid Status</measure>
    <time_frame>Upon study entry and every 6-12 months thereafter for up to ten (10) years</time_frame>
    <description>Self reported and clinically reported corticosteroid status (past and present) will be captured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Status</measure>
    <time_frame>Upon study entry and every 6-12 months thereafter for up to ten (10) years</time_frame>
    <description>Self reported and clinically reported cardiac status (past and present) will be captured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Status</measure>
    <time_frame>Upon study entry and every 6-12 months thereafter for up to ten (10) years</time_frame>
    <description>Self reported and clinically reported respiratory status (past and present) will be captured</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <condition>Becker Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Duchenne and Becker muscular dystrophy</arm_group_label>
    <description>Individuals with Duchenne muscular dystrophy and Becker muscular dystrophy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carriers</arm_group_label>
    <description>Carriers of Duchenne muscular dystrophy and Becker muscular dystrophy</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, Urine, Saliva, Muscle and Skin will be collected. Sample collection will be optional.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals with or carriers of Duchenne muscular dystrophy (DMD) and Becker muscular&#xD;
        dystrophy (BMD).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Any of the following are true:&#xD;
&#xD;
               1. Currently has a confirmed diagnosis of DMD/BMD based on genetic testing, muscle&#xD;
                  biopsy, or clinical diagnosis.&#xD;
&#xD;
               2. Currently has a confirmed diagnosis of carrier status for DMD/BMD based on&#xD;
                  genetic testing.&#xD;
&#xD;
          2. Parent/guardian (for minor participants) or participant gives informed consent and/or&#xD;
             assent as required by local regulations.&#xD;
&#xD;
          3. Is age 4 weeks or older at the time of consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Is a foster child or ward of the state.&#xD;
&#xD;
          2. Is a prisoner.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Debra Miller</last_name>
    <role>Principal Investigator</role>
    <affiliation>CureDuchenne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joanna Kemp</last_name>
    <phone>888-235-4655</phone>
    <email>support@cureduchennelink.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>CureDuchenne</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CD Link Staff</last_name>
      <phone>888-235-4655</phone>
      <email>support@cureduchennelink.org</email>
    </contact>
    <investigator>
      <last_name>Joanna Kemp, BSN, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Debra Miller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.cureduchenne.org/cureduchenne-link/</url>
    <description>CureDuchenne Link Information Page</description>
  </link>
  <link>
    <url>https://cureduchennelink.org/</url>
    <description>CureDuchenne Link Registration Page</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 21, 2021</study_first_submitted>
  <study_first_submitted_qc>July 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2021</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Carrier</keyword>
  <keyword>DMD</keyword>
  <keyword>BMD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After a thorough application process, data will be shared to qualified researchers.&#xD;
Approved researchers will complete all required CDA/data transfer agreements with CureDuchenne. Once complete, they will be given access to a limited dataset with direct identifiers removed.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

